RMTI (Rockwell Medical) Piotroski F-Score: 3 (As of Jun. 26, 2026) — Near Median


RMTI Rockwell Medical Inc RMTI
32 GF Score
Price $0.67
GF Value $0.87
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical Piotroski F-Score?

Rockwell Medical RMTI +3.32% 32 Piotroski F-Score is 3 as of Jun. 26, 2026, which is at its 10-year median of 3.00. GuruFocus rates RMTI with a GF Score™ of 32/100 and a GF Value™ of $0.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Rockwell Medical ranks worse than 78.29% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rockwell Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Rockwell Medical's Piotroski F-Score or its related term are showing as below:

RMTI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Rockwell Medical was 7. The lowest was 2. And the median was 3.

Rockwell Medical  (NAS:RMTI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rockwell Medical Piotroski F-Score Related Terms


Rockwell Medical Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical Piotroski F-Score Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 6.00 4.00 7.00 3.00

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 3.00 3.00 3.00

RMTI vs MRMD, CPHI, HYEX: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Piotroski F-Score falls into.


RMTI
32GF Score
Rockwell Medical Inc RMTI
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.492 + -1.753 + -0.554 + -1.605 = $-5.40 Mil.
Cash Flow from Operations was 1.844 + -1.307 + 2.291 + -0.167 = $2.66 Mil.
Revenue was 16.071 + 15.927 + 18.346 + 17.336 = $67.68 Mil.
Gross Profit was 2.503 + 2.272 + 3.878 + 2.897 = $11.55 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(53.961 + 52.625 + 57.486 + 57.145 + 57.423) / 5 = $55.728 Mil.
Total Assets at the begining of this year (Mar25) was $53.96 Mil.
Long-Term Debt & Capital Lease Obligation was $11.70 Mil.
Total Current Assets was $36.94 Mil.
Total Current Liabilities was $9.87 Mil.
Net Income was 0.343 + 1.664 + -0.756 + -1.515 = $-0.26 Mil.

Revenue was 25.832 + 28.316 + 24.665 + 18.914 = $97.73 Mil.
Gross Profit was 4.55 + 6.239 + 3.631 + 3.042 = $17.46 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(50.723 + 53.028 + 57.084 + 59.208 + 53.961) / 5 = $54.8008 Mil.
Total Assets at the begining of last year (Mar24) was $50.72 Mil.
Long-Term Debt & Capital Lease Obligation was $10.73 Mil.
Total Current Assets was $33.03 Mil.
Total Current Liabilities was $11.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rockwell Medical's current Net Income (TTM) was -5.40. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rockwell Medical's current Cash Flow from Operations (TTM) was 2.66. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-5.404/53.961
=-0.1001464

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-0.264/50.723
=-0.00520474

Rockwell Medical's return on assets of this year was -0.1001464. Rockwell Medical's return on assets of last year was -0.00520474. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rockwell Medical's current Net Income (TTM) was -5.40. Rockwell Medical's current Cash Flow from Operations (TTM) was 2.66. ==> 2.66 > -5.40 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=11.698/55.728
=0.20991243

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=10.734/54.8008
=0.19587305

Rockwell Medical's gearing of this year was 0.20991243. Rockwell Medical's gearing of last year was 0.19587305. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=36.943/9.868
=3.74371707

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=33.034/11.205
=2.94814815

Rockwell Medical's current ratio of this year was 3.74371707. Rockwell Medical's current ratio of last year was 2.94814815. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rockwell Medical's number of shares in issue this year was 39.418. Rockwell Medical's number of shares in issue last year was 34.108. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=11.55/67.68
=0.17065603

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=17.462/97.727
=0.17868143

Rockwell Medical's gross margin of this year was 0.17065603. Rockwell Medical's gross margin of last year was 0.17868143. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=67.68/53.961
=1.25423917

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=97.727/50.723
=1.9266802

Rockwell Medical's asset turnover of this year was 1.25423917. Rockwell Medical's asset turnover of last year was 1.9266802. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rockwell Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Rockwell Medical (RMTI) has a Piotroski F-Score of 3 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rockwell Medical and its competitors. This is near median its historical median of 3.00. Over the past decade, Rockwell Medical's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Rockwell Medical ranks #768 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Rockwell Medical's Piotroski F-Score too high?
Rockwell Medical's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Rockwell Medical's value of 3 is 40% below this industry median. Based on the distribution chart, Rockwell Medical ranks #768 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Piotroski F-Score compare to MRMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #768 out of 981 companies for Piotroski F-Score. This places Rockwell Medical in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Rockwell Medical's value of 3 is 40% below this benchmark. Historically, Rockwell Medical's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Rockwell Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (RMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.87, compared to a current price of $0.67 — trading 22.7% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Drug Manufacturers industry median of 5.00. Rockwell Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Rockwell Medical (RMTI), the current Piotroski F-Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (RMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued. The current stock price of $0.67 is trading 22.7% below its estimated GF Value™ of $0.87. GuruFocus considers Rockwell Medical to be Modestly Undervalued.

Key valuation signals for RMTI:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: $0.87 vs. price of $0.67 (22.7% below fair value)
  • GF Score™: 32/100 with 3 warning signs
  • Industry Position: 40% below the Drug Manufacturers median (#768 of 981)

No single metric tells the full story. See the RMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rockwell Medical Business Description

Other Exchanges RWMA:Germany
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
32GF Score

Get the complete analysis for RMTI

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price
$0.87
GF Value